Can a Two-Drug cocktail stop Chemo-Linked nausea before it starts?
NCT ID NCT07726433
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This trial is testing whether a combination of two drugs, fosrolapitant and palonosetron, can prevent nausea and vomiting in cancer patients receiving trastuzumab rezetecan therapy. About 56 adults scheduled for this targeted treatment will receive the antiemetic combination intravenously before chemotherapy. Researchers will track vomiting episodes and nausea severity over two treatment cycles to see if the regimen works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of fosrolapitant and palonosetron hydrochloride given as an IV injection
- What this could lead to
- If effective, this antiemetic regimen could offer a new way to prevent nausea and vomiting in patients receiving trastuzumab rezetecan, improving treatment tolerability.
- What could go wrong
- This is a small, early-phase exploratory trial without a placebo group, so results may not confirm effectiveness. Side effects from the antiemetic drugs themselves are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Cancer Hospital Airport Hospital
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.